Avalo Therapeutics, Inc. current report, 05 March 2019

Business Context and Reporting Period

This Form 8-K was filed by Cerecor Inc. on March 5, 2019. The registrant is a Delaware corporation and an emerging growth company. The report details the entry into a material definitive agreement regarding a public offering of common stock.

Key Financial Metrics and Transaction Details

The filing discloses a specific equity financing transaction rather than periodic financial performance metrics (revenue, profit, or cash flow).

  • Shares Sold: 1,818,182 shares of common stock.
  • Offering Price: $5.50 per share.
  • Over-Allotment Option: A 45-day option granted to the underwriter to purchase up to an additional 272,727 shares at the same price.
  • Underwriting Fees: 7% underwriting discount plus 0.5% management fee on gross proceeds.
  • Expense Reimbursement: $75,000 paid to the underwriter.
  • Underwriter: H.C. Wainwright & Co., LLC (sole book-running manager).
  • Expected Closing: On or about March 8, 2019.

Material Changes

The primary material change is the execution of the underwriting agreement to raise capital through the sale of common stock. The filing text does not provide comparative financial data or prior period metrics to quantify changes in revenue, margins, or debt levels.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard representations and warranties customary in underwriting agreements. The transaction is subject to the closing date and the exercise of the over-allotment option.

Investor Verification Checklist

  • Verify the actual closing date of the offering (anticipated March 8, 2019) and the final number of shares sold.
  • Confirm whether the underwriter exercised the 45-day option to purchase the additional 272,727 shares.
  • Review the final prospectus supplement (dated March 6, 2019) for updated use of proceeds.
  • Check subsequent filings for the impact of this capital raise on the company's cash position and dilution.